Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TOP2A | P11388 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11921724 | 0.82 | MAOB (0.57) | TSHRCYP1A2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL30184432 | 0.82 | CYP1A1 (0.42) | CYP1A1CYP1B1CYP1A2POLBABCB1 | |
| SCHEMBL827785 | 0.80 | MAOB (0.42) | TSHRCYP1A1CYP1B1CYP1A2ALDH1A1 | |
| SCHEMBL1380870 | 0.79 | PLK1 (0.54) | CYP1A1CYP1B1CYP1A2POLBHPGD | |
| SCHEMBL269277 | 0.78 | MAOB (0.49) | TSHRCYP1A1CYP1B1CYP1A2ALDH1A1 | |
| SCHEMBL2047943 | 0.78 | CYP1A1 (0.47) | LMNATSHRCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL6682006 | 0.78 | CYP1A1 (0.39) | TSHRCYP1A1CYP1B1CYP1A2ALDH1A1 | |
| SCHEMBL72202 | 0.77 | MAOB (0.55) | LMNATSHRALDH1A1KDM4EHPGD | |
| SCHEMBL70429 | 0.77 | LMNA (0.59) | LMNATSHRALDH1A1CFTRHSD17B10 | |
| SCHEMBL15842329 | 0.77 | CYP2A6 (0.57) | LMNATSHRALDH1A1CFTRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4194451-A1 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-4148053-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | The Global Alliance for TB Drug Development, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-10981891-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981891-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040198980-A1 | Selective rxr ligands | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1430042-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SmithKline Beecham Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
| EP-1326860-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003047584-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047585-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003027090-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | LMNA 761/4885TSHR 2438/4885CYP1A1 202/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | LMNA 2392/4885TSHR 3422/4885CYP1A1 479/4885 |
| US-10981891-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | LMNA 2694/4885TSHR 2596/4885CYP1A1 949/4885 |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CFTR, SQOR, NQO1 | LMNA 2694/4885TSHR 2596/4885CYP1A1 949/4885 |
| US-20040198980-A1 | Selective rxr ligands | RXRA, RXRB, RXRG | LMNA 4181/4885TSHR 81/4885CYP1A1 903/4885 |
| US-10508097-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | LMNA 2694/4885TSHR 2596/4885CYP1A1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.